Indivior INDV
Indivior Q3 FY25: revenue $314.0M; diluted EPS $0.33
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001628280-25-047530
Key figures from this report
These are the numbers Indivior reported for Q3 FY25, the quarter ended Sep 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$314.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Net income$42.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS$0.33No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$445.0MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$39.0MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Apellis Pharmaceuticals APLS public float $1.8B, Jun 30, 2025
- Biocryst Pharmaceuticals BCRX public float $1.9B, Jun 30, 2025
- Agios Pharmaceuticals AGIO public float $1.9B, Jun 30, 2025
- Amicus Therapeutics FOLD public float $1.7B, Jun 30, 2025
- Supernus Pharmaceuticals SUPN public float $1.7B, Jun 30, 2025